Table 4.
Information exploration over time (t) in Test Phase 1 for Cold group
| Feature | t1 (%) | t2 (%) | t3 (%) | t4 (%) | t5 (%) | t6 (%) | t7 (%) | t8 (%) | t9 (%) | t10 (%) | t11 (%) | t12 (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price | 1.0 | 2.1 | 5.0 | 5.7 | 11.0 | 11.1 | 19.1 | 22.0 | 26.6 | 26.6 | 26.4 | 23.5 |
| Brand | 3.6 | 4.8 | 5.0 | 5.1 | 2.5 | 4.2 | 10.9 | 10.2 | 26.6 | 24.4 | 32.3 | 38.2 |
| Side effect | 41.0 | 44.3 | 30.1 | 28.6 | 16.9 | 17.9 | 9.5 | 11.7 | 4.4 | 2.2 | 11.7 | 11.7 |
| Daily dose | 7.3 | 7.5 | 20.7 | 21.6 | 29.6 | 30.7 | 24.6 | 19.1 | 15.5 | 15.5 | 5.8 | 5.8 |
| Doctor’s advice | 41.0 | 35.1 | 29.5 | 29.3 | 19.4 | 16.2 | 17.8 | 14.7 | 2.2 | 2.2 | 8.8 | 5.8 |
| Availability | 5.7 | 5.9 | 9.4 | 9.5 | 20.3 | 19.6 | 17.8 | 22.0 | 24.4 | 28.8 | 14.7 | 14.7 |
| Active trials | 100.0 | 97.3 | 83.6 | 82.6 | 62.1 | 61.5 | 38.4 | 35.7 | 23.6 | 23.6 | 17.8 | 17.8 |